


Global Unitaid approach to reduce preventable HIV mortality

*Dr. Yamuna Mundade
Programme Manager
Unitaid, Geneva, Switzerland*

04/Nov/2024

Workshop on `Uniting science and communities to accelerate the HIV response in
the Carribean`
IAS Educational Fund / PANCAP

**We are a pathfinder, investor
and influencer**



Our (lead) implementing partners



Our donors



Brazil



Chile



France



Japan

BILL & MELINDA
GATES foundation



Norway



Republic of Korea



Spain



United Kingdom



Canada



Germany



Italy




Portugal

Unitaid active portfolio end-2023 (by area)

Total portfolio value of US\$1.60 billion

- HIV & coinfections
- Tuberculosis
- Malaria
- Women's & children's health
- Global health emergencies (PPPR)
- Cross-cutting



How we work



Unitaid's strategic objectives


Products, access, and people

- 1** Accelerate the introduction and adoption of key health **products**
- 2** Create systematic conditions for sustainable, equitable **access**
- 3** Foster inclusive and demand-driven **partnerships** for innovation


Children holding some of the first appropriately dosed, child-friendly paediatric TB medicines funded by Unitaid. © TB Alliance



Unitaid's operating model



Unitaid's Programmatic Priorities




Global targets: By 2030, 95% of PLHIV who know their status initiate treatment and 95% on treatment are virally suppressed (86% and 72% respectively in 2023)

Summary of the Global HIV epidemic, 2023


	People living with HIV	People acquiring HIV	People dying from HIV related causes
Total	39.9 million [36.1-44.6 million]	1.3 million [1.0-1.7 million]	630 000 [500 000-820 000]
Adults (15+ years)	38.6 million [34.9-43.1 million]	1.2 million [950 000-1.5 million]	560 000 [430 000-730 000]
Women (15+ years)	20.5 million [18.5-22.9 million]	520 000 [400 000-690 000]	240 000 [180 000-320 000]
Men (15+ years)	18.1 million [16.2-20.3 million]	660 000 [540 000-840 000]	320 000 [250 000-420 000]
Children (<15 years)	1.4 million [1.1-1.7 million]	120 000 [83 000-170 000]	76 000 [53 000-110 000]

Source: UNAIDS/ WHO estimates, 2024

Progress towards achieving the HIV testing, treatment and viral load suppression cascades targets among people living with HIV, globally and by WHO region, 2023



The HIV Portfolio over time



HIV and Co-infections Programmatic Priorities

1. Sustain effectiveness of prevention and treatment - ART
2. Sustain effectiveness of prevention and treatment - PrEP
3. Accelerate access to self-testing and integrated diagnostics
4. Optimize and enable scale of AHD packages of care
5. Drive HCV elimination through testing and prevention
6. Screen and treat for cervical cancer and STIs

Cross-cutting support: Long-acting technologies, IP grants including MPP, and regulatory including WHO PQ

Current HIV and Co-infections portfolio in summary:

\$394M

Invested

15

Projects

37

Countries

Lead implementing partners



Unitaid's HIV Prevention portfolio

Pre-exposure prophylaxis

Active:

- Wits RHI
- Fiotec

Recently closed:

- MTV Staying alive Foundation

Peri and post natal prevention

Active:

- Wits RHI

Open call:

- Triple elimination

Recently closed:

- University of Liverpool

Harm reduction

Active:

- Frontline AIDS
- Medecines du monde
- PATH

Enabling elements

Active:

- Medicines Patent Pool
- IP grants
- WHO Prequalification
- WHO Enabler

Sustain effectiveness of prevention and treatment: PrEP Overview

Our expected results

- **Evidence generated on effective delivery approaches** for various PrEP technologies including oral PrEP, dapivirine vaginal ring (DVR), long-acting injectable cabotegravir (CAB-LA); as well as management of sexually transmitted infections (STIs).
- **Awareness generated** among policy makers and demand created among potential beneficiaries for uptake of various PrEP technologies and management of STIs.
- **PrEP integrated** as an entry point into a comprehensive prevention package including the integration of services for STIs.
- **Supply-side barriers overcome** to enable access to long-acting PrEP, including CAB-LA, DVR, as well as future ones.

Focus products

- Oral PrEP
- CAB-LA
- DVR
- Other long-acting PrEP products

Focus populations

- Men who have sex with men (MSM)
- Transgender people (TG)
- Adolescent MSM and TG
- Adolescent young girls and women (AYGW)

Unitaid's HIV Diagnostics portfolio

HIV testing

Active:

- STAR PSI Self testing
- FIND-RDT manufacturing

Closed:

- Atlas – Solthis self testing
- MTV Self testing
- UPOC VL/ EID

HIV Co-infections & co-conditions

Active:

- STAR PSI – (HCV, C-19)
- AHD grants (TB, Crypto, SBIs)
- PrEP (STIs)
- CxCa (STIs)
- Triple elimination

Enabling elements

Active:

- WHO Enabler
- WHO RPQ
- GF ERPD and Next gen MS

To be activated:

- African society for lab med
- AFI on integrated diagnostics

Accelerate access to HIV self-testing and diagnostics: Overview

Our expected results

- **Evidence generated on acceptability, feasibility, and cost-effectiveness of self-testing delivery approach** to inform WHO normative guidance and country level adoption.
- **Market created; Supply chain barriers addressed, and demand created through real-life implementation and promote uptake by priority population** targeting those who are not reached by the standard of care, including through MTV edutainment.
- **Favorable market exists** to promote affordable, sustainable supply diversity and security for HIVST oral- and blood-based products and achieve healthy, competitive markets across the WHO prequalified HIVST products.

Focus products

- Oral fluid HIVST
- Blood-based HIVST
- HCV self-tests
- Self-care tools that link with prevention

Focus populations

- People with ongoing risk of acquiring HIV or who remain undiagnosed, e.g., men; adolescents; commercial sex workers; people who use drugs; men who have sex with men.

Unitaid's HIV Treatment and AHD portfolio

Global target: By 2030, 95% of PLHIV who know their status initiate treatment and 86% on treatment are virally suppressed (86% and 72% respectively in 2023)

Anti-retroviral Therapy Optimization

Active:

- University of Stellenbosch- DTG oral film neonates
- CHAI pDRV/r Development Program
- University of Washington- LA TLD

Recently Closed:

- CHAI Optimal
- RCTs:
 - Institut Bouisson Bertrand
 - Kirby Institute
 - Ezintsha
 - University of Liverpool

AHD

Active:

- CHAI
- AURUM Institute

Recently Closed:

- CHAI OPTIMAL

Enabling Elements

Active:

- WHO Enabler
- PAHO Enabler
- Medicines Patent Pool
- IP grants
- WHO Prequalification

To be activated:

- PAHO Enabler
- RMI

Sustain effectiveness of prevention and treatment: ART overview

Our expected results

- **Evidence generated** on safety and efficacy of optimal HIV treatment regimens in LMIC settings **and disseminated**.
- **WHO and national treatment guidelines recommending** optimal HIV treatments as preferred first- and second-line options for adults and children.
- **Affordable and adapted products** available through market shaping (price reduction, competition and product development).
- **Accelerated development and market entry** of optimal HIV treatment products, including (i) new paediatric formulations and (ii) other niche products (second-line treatment).
- **Accelerated introduction, adoption and uptake** of optimal and affordable HIV treatments in countries, including through (i) community awareness and demand generation, and (ii) country preparedness and roll-out support for priority products.

Focus products

- Adults: EFV400, TDF/XTC/EFV400, TDF/XTC/DTG and TAF/XTC/DTG; DRV/r
- Paediatric: pDTG 10mg, ALD, pDRV/r

Focus populations

- Diverse populations (including women of childbearing potential, people with HIV/TB co-infections)
- Children (from infancy to adolescence)

Optimize and enable AHD packages of care: overview

Our expected results

- **Increased affordability of focus products** through catalytic procurement and engaging with manufacturers to lower prices and optimize costs.
- **Improved supply and delivery** including through registration of products in country and improved demand forecasting and coordination, budgeting, and procurement planning. **Pathway developed for exploratory regional manufacturing** of selected AHD products.
- **Enabling environment for product demand and uptake**, including updated national policy documents, operational plans, and/or training/mentoring toolkits.
- **Increased availability** of optimal products, including generics, at LMIC health facilities and community levels.
- **Evidence on operational feasibility** of decentralized delivery models and paediatric STOP AIDS toolkit in health systems in a range of geographies.

Focus products

- Diagnostic tests to identify people with AHD; screen and diagnose main OIs: TB, cryptococcal meningitis (CM), histoplasmosis.
- Optimal treatment and prevention products (5FC, L-AmB) for CM and TB.

Focus populations

- PLHIV with AHD, particularly with TB, CM, and severe bacterial infections. Children and adolescents with HIV.

Progress achieved during Phase-1 of AHD investments

Key achievements of the Unitaid-CHAI AHD initiative (2019-2023)

- **Price reduction** of priority health products, eg: 5.FC, L-AmB
- **Catalytic procurement and product introduction support** (product registration etc), for L-AmB, 5-FC, CrAg LFA, TB LAM and an early market access vehicle for CD4 LFA
- **Market coordination:** coordinating procurement and providing market visibility
- **Décentralisation of screening:** increasing access to same-day AHD screening; hub and spoke model for treatment
- **Supply security of optimal AHD treatment** (incl. additional catalytic procurement)
- **Demand generation** amongst healthcare workers and PLHIV community groups
- **Transition of AHD programs** to MOHs, and **scale-up partner funding**

Focal products	
Drugs	Diagnostics
Fluocytosine	RDT CD4
Liposomal amphotericin B	Device based CD4
Fluconazole	TB LAM
TPT	CrAg LFA

Unitaid's HIV treatment and AHD portfolio – Phase 1

Population	Projects	Related 2025 Targets	Endline Status (2022 data)
Adults and Adolescents	OPTIMAL (CHAI) NAMSAL (IBB) D2EFT (Kirby Institute) ADVANCE (Ezintsha)	95% of PLHIV who know their status initiate treatment 95% on treatment are virally suppressed	89% (of 86% knowing serostatus) 93%
	THRIVE (CHAI) IMPAACT4HIV (AURUM) <i>PAHO Enabler (PAHO)</i>	Reduce the annual number of AIDS-related deaths to 250,000	540,000
Pregnant and lactating populations	DoLPHIN2 (University of Liverpool)	All PBFW living with HIV receiving ART, with 95% achieving and sustaining viral suppression before delivery and during breastfeeding	82% of PBFW living with HIV receiving ART
Children	OPTIMAL (CHAI) THRIVE (CHAI) IMPAACT4HIV (AURUM)	95% of CLHIV who know their status on treatment; 95% on treatment are virally suppressed	63% of CLHIV know their status, 57% of CLHIV on ART (91%) 46% of CLHIV virally suppressed (81%)
	THRIVE (CHAI) IMPAACT4HIV (AURUM)	End AIDS among children	84,000 AIDS related deaths < 15 years, 130 000 new infections

AHD Phase-2 of Unitaid investments: Objectives

- **Introduction of emerging tools that could implement the current care package recommended by WHO for adults and adolescents living with HIV to:**
 - Enable further simplification in selected early-adopter countries
 - Enable early management of main drivers of death that remain unaddressed (DH, SBIs) and/or that can be further optimized with recent products entering the market (CM).
- **Innovative approaches to improve implementation and enable increased utilization of STOP-AIDS toolkit to prevent, diagnose and treat AHD-associated Ois in paediatric populations through:**
 - Pilots that address key policy adoption, procurement and supply, and service delivery barriers
 - Demand generation activities with policy-makers, providers and patients
 - Generate impact, cost effectiveness and operational feasibility evidence to support delivery at scale
 - Ancillary efforts that increase access to other tools


AHD current grant portfolio

	AURUM	CHAI	PAHO
Name	IMproved Access for AHD Care and Treatment for HIV – IMPAACT4HIV	Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access – THRIVE	Preventing deaths among adults and children by optimizing Advanced HIV Disease management PAHO Enabler
Consortium	<ul style="list-style-type: none"> • DNDi • MAA (Market Access Africa) • PATA (Paediatric-Adolescent Treatment Africa) • Solthis (Solidarité Thérapeutique et Initiatives pour la Santé) 	<ul style="list-style-type: none"> • Afrocab • Penta 	<ul style="list-style-type: none"> • N/A
Countries	Cote d’Ivoire, DRC, Mozambique, Nigeria, Sierra Leone, South Africa	Kenya, Mozambique, Nigeria, South Africa, Uganda, Zimbabwe	Latin America and the Caribbean. Special focus on Argentina, Brazil, Cuba, Dominican Republic, Ecuador, Guatemala, Guyana, Honduras, Peru, Paraguay, and Uruguay
Timeline	3.5 years End Date: December 2026	3 years End Date: June 2027	2.5 years End Date: December 2026

Continued grants: WHO Enabler, contributing elements from TB investments, legacy pediatric ART in CHAI Optimal.

AHD portfolio theory of change alignment with Unitaid Strategic Objectives

Programmatic Priority: Optimize and enable scale of AHD packages of care



Expected Outputs of the AHD Portfolio

Evidence generation

- › **6** countries generating evidence on **STOP AIDS Toolkit/paediatric AHD Care package delivery**
- › **4+** countries generating evidence on **Adult AHD care packages incorporating new tools**
- › Use cases for new tools, such as CrAg SQ, Digital readers tested

Supply side interventions

Procurement:

- › **CrAg SQ/CrAg LFA**
- › **Histoplasmosis LFA**
- › **L-AmB**
- › **Itraconazole**
- › **CD4 LFA**

Implementation:

- › health facilities targeted
- › Community access points reached
- › cases linked to AHD care packages

Country readiness and transition support

- › **84%** LMICs updating AHD policies/guidelines/plans
- › **75%** LMICs procuring priority products
- › **75%** of eligible population benefiting from optimized products

Community engagement, demand generation

- › **Effective and accelerated pathways for product introduction that are fit-for-purpose**






Global Advocacy and partner coordination


- › Countries **securing additional resources** to support transition and scale-up of AHD care packages solutions

Broad range of stakeholders engaged, including national and sub-national governments, NGOs/CSOs and community groups, health care workers, external donors/scale up partners, community health advisory boards, community leaders




IMPAACT4HIV consortium comprises six partner organizations providing global and country focused technical support across six countries in SSA

IMPAACT4HIV Consortium

	TECHNICAL PARTNERS	ROLE	DELIVERY FOCUS COUNTRIES
	AURUM	Consortium Lead	Technical delivery Mozambique, **South Africa, **Nigeria CCSE manager – All countries
	Paediatric Adolescent Treatment Africa	CCSE Paeds TA	NGA, **South Africa, Mozambique, Cote D'Ivoire
		CCSE Manager	Mozambique, **South Africa, **Nigeria
ALL	Market Access Africa	Market Access	All countries
	Centre for Integrated Health Programs	Aurum delivery Partner	**Nigeria
	Drugs for Neglected Diseases Initiative	Implementing Partner	DRC
			Cote D'Ivoire, Sierra Leone
	Solidarité Thérapeutique et Initiatives pour la Santé		



Key

-  Paediatrics (0-14) package**
-  Adults & Adolescents package
-  Adults & Paeds package

**Joint country-level delivery with CHAI THRIVE

FOCUS COUNTRIES

- Contribute $\frac{1}{4}$ to the global deaths: **168,300 deaths in 2022**^{1,2}
- Limited rollout of decentralized, differentiated delivery: Cote D'Ivoire, Sierra Leone, DRC,
- Limited roll out of 3HP and 5FC:
- Quality of care for improved outcomes: Nigeria, South Africa, Mozambique

**Joint country-level delivery with CHAI THRIVE






The CHAI consortium with Afrocab and Penta aims to dramatically reduce mortality among adults and children living with HIV by enabling access to critical prevention, screening, and treatment commodities

THRIVE: Transforming Advanced HIV Disease Care in LMICs through Comprehensive and Equitable Access

The consortium will tackle access barriers at the global, regional, national, and community levels for adults and pediatrics.

Project Focal Areas

Project timeline: January 2024 – Dec 2026

- 1** **Generate evidence** to inform iterative policy and implementation approaches for the STOP AIDS package 
- 2** **Accelerate access to and improve usability of** new and focal AHD products and commodities through supply-side interventions 
- 3** Partner with MOHs to **facilitate country readiness and transition** by implementing the STOP AIDS package and improving AHD services 
- 4** **Lead end-to-end community engagement and demand generation** to effectively deliver AHD services 
- 5** **Advocate globally and coordinate partners** to prioritize pediatric AHD on the global agenda 

Focal Countries

Kenya, Mozambique*, Nigeria, South Africa, Uganda, Zimbabwe



Focal Populations



Addressing the high burden of mortality amongst **children living with HIV** and gaps in guidance and global prioritization



Targeting service delivery gaps and realizing the impact of new products to address AHD for **adults & adolescents with HIV**

Anticipated Impact Across the Unitaid AHD Portfolio

>**50,000** lives saved during the project, over 50% of which will be children

>**150,000** lives saved during the project and 5 years post



AFROCAB



WHO Enabler grants: 2017 to date


- Unitaid will continue to co-operate with WHO as per Unitaid strategy 2023-27, on several programmatic priorities, in line with WHO strategies for HIV, Viral Hepatitis, sexually transmitted infections, TB, Malaria and cervical cancer

Area	Unitaid Programmatic Priority	WHO Workstream	
HIV&COIMS	Prevention & treatment	ART	
		PrEP	
	Advanced disease	AHD	
	Self-testing and integrated diagnostics	Self-testing	
		Integrated diagnostics	
	Hepatitis C	HCV	
Cervical cancer & STIs	CxCa		
TB	Diagnostics	Dx	
	Prevention	TPT	
	Treatment	MDR-TB	
Malaria	Prevention	Vector control	IPTi
	Case management	P. vivax	

Co-chaired by WHO and CDC

The Advanced HIV Disease Alliance

Formerly the AHD ISC



Being updated to include new donors and new implementers, broader country representation and specific attention to children and access/market through dedicated discussions.



THANK YOU!

04/Nov/2024